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Abstract
Background: Any metal placed in a biological environment undergoes corrosion. Thus, with their
large metallic surfaces, TKA implants are particularly prone to corrosion with subsequent release
of metal ions into the human body which may cause local and systemic toxic effects and
hypersensitivity reactions, and increase cancer risk. To address this problem, a new 7-layer
zirconium coating developed especially for cobalt-chrome orthopaedic implants was tested
biomechanically and found to lower metal ion release.
The purpose of the proposed clinical trial is to compare the metal ion concentration in patients'
plasma before and after implantation of a coated or uncoated TKA implant.
Methods/Design: In this randomised controlled trial, 120 patients undergoing primary TKA will
be recruited at the Department of Orthopaedic Surgery of the University Hospital in Dresden,
Germany, and randomised to either the coated or uncoated prosthesis. Outcome assessments will
be conducted preoperatively and at 3 months, 12 months and 5 years postoperatively. The primary
clinical endpoint will be the chromium ion concentration in the patient's plasma after 1 and 5 years.
Secondary outcomes include cobalt, molybdenum and nickel ion concentrations after 1 and 5 years,
allergy testing for hypersensitivity against one of these metals, the Knee Society Score to assess
clinical and physical function of the knee joint, the self-assessment Oxford Score and the Short
Form 36 quality of live questionnaire.
Discussion: The metal ion concentration in the patient's plasma has been shown to increase after
TKA, its eventual adverse effects being widely debated. In the light of this discussion, ways to
reduce metal ion release from orthopaedic implants should be studied in detail. The results of this
investigation may lead to a new method to achieve this goal.
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Background
Total knee arthroplasty (TKA) is a very successful treat-
ment option for advanced osteoarthritis of the knee with
about 146.000 operations performed in 2008 in Germany
[1]. Although patients obviously benefit from joint
replacement in terms of mobility and quality of life,
implant-specific local and systemic adverse effects, due to
corrosion and wear, still constitute a matter of concern [2-
6]. Besides polyethylene wear which is one cause for asep-
tic loosening, metal ion release from metallic implants is
also subject of debate. Every metal implant in a biological
environment corrodes, depending on the exposed surface
area and the composition of the alloy [7]. This process
results in the release of metal ions.
It has been suggested that metal ion release may trigger
local and systemic toxic effects [8] and hypersensitivity
reactions [9-12]. Furthermore, in animal studies, cobalt
and chromium ion exposure was found to have carcino-
genic and mutagenic effects. Therefore, cancer risk may
increase from exposure to the cobalt and chromium ions
released by metal implants [13-15]. In contrast to these
experimental data, epidemiologic studies did not find a
greater risk of developing a malignancy after TKA
[6,16,17]. However, increases in lymphoma, cancer of the
endometriuma and prostate and skin melanoma were
observed that could be related to TKA [16,17].
As they contain large metallic surfaces, TKA implants are
particularly subject to corrosion inducing release of metal
ions. Significantly higher metal ion concentrations were
detected in patients after TKA compared to patients with-
out metal implants [18]. Attempts have been made to
reduce metal ion release and to improve the tribological
properties of TKA implants by coating the chrome-cobalt
body with various zirconium compositions, especially
designed for patients with metal hypersensitivity. In in-
vitro biomechnical tests, they showed superior tribologi-
cal characteristics and thus less polyethylene wear parti-
cles [19-22]. However, in clinical tests, they presented
early radiolucent lines [23] and achieved less favourable
results in the Australian TKA registry [24].
To reduce ion release, a new multilayer coating system
was developed consisting of a thin adhesive chrome layer,
five alternating intermediate layers out of chrome nitride
(CrN)-chrome carbonitride (CrCN) and a final shielding
zirconium nitride (ZrN) layer.
The 7-layer coating system is applied on the CoCrMo knee
implants through the chemical vapour deposition (CVD)
method with a total thickness of about 3,5 to 6 μm. The
gradiently applied CrN-CrCN layers allow to bridge the
difference in hardness and tension between the softer
material CoCrMo and the very hard ZrN shielding layer
and thus ensure the system's mechanical integrity. The
interfaces between the layers constitute an additional dif-
fusion barrier against ions from the base material. In addi-
tion, the final ceramic ZrN layer seals the system and is
highly biocompatible.
To evaluate its abrasive properties, it was tested in an in-
vitro simulation according to ISO 14243-1:2002(E)
through 5 million cycles with a frequency of 1 Hz.
Nickel and molybdenum ion release of the ZrN-coated
implants into the wear test serum was reduced to the
point that traces of these elements were found only within
the range of detection levels while only minimal traces of
cobalt and chrome were detected in the test serums, infe-
rior by orders of magnitude to those of the uncoated
implants out of CoCrMo [25].
Therefore, this surface coating could help to significantly
reduce release of metal ions in TKA patients.
The aim of this study is to compare this novel surface coat-
ing with the standard CrCoMb-alloy in terms of metal ion
levels in patients' plasma, metal hypersensitivity and clin-
ical and radiological results.
Study Hypothesis
The study's hypothesis is that metal ion concentrations in
the patient's plasma will be significantly lower in the
group receiving the ZrN-coated implant than in the other
group.
Methods/Design
This study is a single-centre randomised controlled trial
that will be conducted at the Medical Faculty of the Tech-
nical University of Dresden. The study protocol was
approved by the local independent Ethics Committee in
February 2009 and registered in the US National Institutes
of Health's database http://www.clinicaltrials.gov registry
under NCT00862511.
The trial is performed according to the guidelines for
Good Clinical Practice (GCP), as applicable.
Inclusion and Exclusion Criteria
Potential participants will be screened and recruited at the
orthopaedic pre-admission clinic.
Inclusion criteria are: (i) indication for TKA in cases of pri-
mary or secondary osteoarthritis, (ii) written informed
consent. Exclusion criteria include (i) metal implants or
endoprostheses, (ii) hypersensitivity against metals or
bone cement particles, (iii) any form of malignancies,
(iiii) renal insufficiency, (iiiii) other severe illnesses that
would impair participation in this study. All eligibleBMC Musculoskeletal Disorders 2009, 10:128 http://www.biomedcentral.com/1471-2474/10/128
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patients will be asked whether they are willing to partici-
pate in the trial and, if so, required to provide a written
informed consent. They will be informed about the pur-
pose of the trial, the operative procedures as well as their
options and risks. They will be randomised to either a
coated or uncoated TKA implant (Columbus, Aesculap,
Tuttlingen, Germany, see figure 1 & 2) using a randomisa-
tion list.
Operative Procedure
In all cases, the coated or uncoated model of a cemented
unconstrained total knee prosthesis with a fixed polyeth-
ylene insert is implanted. Both implants are CE-certified.
All operations are performed with a tourniquet after a sin-
gle dose of antibiotics (1.5 g Cefuroxim), using a medial
parapatellar approach with a femur-first preparation.
Femoral alignment in the frontal plane is is directed at an
angle of 90° to the mechanical axis in the frontal plane.
For sagittal alignment, it is placed parallel to the ventral
femoral cortex and, for rotational alignment, parallel to
the transepicondylar axis. Tibial alignment is directed at
an angle of 90° to the mechanical axis in the frontal
plane, with a 5° posterior slope in the sagittal plane and
at the medial third of the tibial tubercle for rotational
alignment. Postoperatively full weight-bearing is allowed,
and mobilisation starts from the first postoperative day.
Clinical Endpoints
The primary endpoint of this investigation is the differ-
ence in chromium ion concentration in the patient's
plasma after 1 and 5 years. Secondary endpoints are the
differences in cobalt, molybdenum and nickel ion con-
centration after 1 and 5 years and a possible hypersensitiv-
ity against one of these metals after 1 year postoperatively.
The metal ion concentrations are to be analysed for a
potential correlation to biomechanical factors (BMI,
mechanical axis), activity (UCLA), function (KSS) and
quality of live (Oxford Score, SF 36).
View of the Columbus knee system (Aesculap, Tuttlingen,  Germany) Figure 1
View of the Columbus knee system (Aesculap, Tut-
tlingen, Germany).
View of the the ZrN-coated Columbus AS knee system (Aes- culap, Tuttlingen, Germany) Figure 2
View of the the ZrN-coated Columbus AS knee sys-
tem (Aesculap, Tuttlingen, Germany).BMC Musculoskeletal Disorders 2009, 10:128 http://www.biomedcentral.com/1471-2474/10/128
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The patients will be clinically examined preoperatively
and 3 months, 1 year and 5 years after surgery. They will
be asked to complete the Knee Society score, the Oxford
Knee score, the Short Form 36 and the UCLA activity score
questionnaires. They will be tested for hypersensitivity
against metal ions preoperatively and one year postopera-
tively. They will be contacted by phone 2, 3 and 4 years
postoperatively and asked to complete the Oxford Knee
score questionnaire. Adverse and serious adverse events
will be evaluated according to Good Clinical Practice (see
table 1 for details).
Metal Ion Analysis
Blood samples are collected in 7,5 ml S-Monovette® tubes
(for trace metal analysis, Sarstedt AG, Germany) using a
specific steel needle for trace metal analysis (Sarstedt AG,
Germany). Within one hour, plasma is separated by cen-
trifugation at 2000 g for 10 min. Samples are stored at -
20°C before being analysed for chromium, cobalt,
molybdenum and nickel content using a graphite furnace
atomic absorption spectrometer Z-8270 with Polarisa-
tion-Zeeman-Absorption (Hitachi Ltd., Japan) [26,27].
Calibration is performed by the standard addition
method using 0.00 μg/l, 5.00 μg/l and 10.00 μg/l as cali-
bration points in triplicate for each element. The samples
are diluted 1:2 in buffer (1% HNO3 [Merck AG, Ger-
many], 0.2% Triton X-100 [SIGMA-Aldrich Chemie
GmbH, Germany], 0.2% Antifoam B [SIGMA-Aldrich
Chemie GmbH, Germany]; Cr and Co: additional 0.8%
Pd-matrix-modifier [Merck AG, Germany], 0.3% Mg-
matrix-modifier [Merck AG, Germany]). The accuracy and
precision of the method is validated to < 10% using the
control materials Seronorm™ Trace Elements Serum
(SERO AS, Norway). The detection limit of the method is
estimated at 0.5 μg/l for each element (mean +3sd from
buffer). The Dixon test was used to eliminate aberrant val-
ues. All probes having ion levels below the detection lev-
els are adjusted to <0.25 μg/l.
Sample Size Considerations
To estimate the number of cases, own data from a cross-
sectional study of patients with a CrCoMb alloy TKA was
used [18]. The chromium ion concentration in the
patient's plasma 5 to 7 years postoperatively was in aver-
age 0.92 μg/l (interquartile range 0.73 - 1.32 μg/l). For the
difference between an uncoated and a ZrN-coated pros-
thesis, the data of a biomechanical study [25] was used.
This in-vitro test demonstrated a 40 times higher chro-
mium ion release in the uncoated implant. 3 coated and
3 uncoated implants were tested and the serum after 1
million loading cycles was taken for the measurement of
metal ion concentration. The chromium ion concentra-
tions was 201 μg/l for the uncoated implant and 4.5 μg/l
for the coated implant.
Taking into account that a normal distribution of data can
not be assumed, the relatively high age of the patients and
an expected drop-out rate of 25%, the necessary number
of cases was estimated at 60 patients per group when a sig-
nificance level of 5% and a test strength of 80% are
required.
Data Acquisition and Management
Patients will be interviewed by a local study nurse pre-
operatively and at specified time intervals postoperatively
(see table 1 for details). In addition to the written inter-
view, the Knee Society score, the Oxford Knee score, the
Short Form 36 and the UCLA activity score will be
recorded.
Data will be entered in prepared CRFs and then trans-
ferred to a SPSS database and subjected to range and plau-
sibility checks. Data reported on the CRF derived from
source documents (e.g. operative report) should be con-
sistent with the source documents or the discrepancies
should be explained.
The clinical database, including all information until 5
years postoperatively, will be closed after the 5-year fol-
low-up visit of the last patient enrolled into the trial. There
will be an interim analysis after the 1-year follow-up visit
of the last enrolled patient which includes the evaluation
of the primary endpoint and the secondary endpoints.
Table 1: Summary of the study parameters
Preop. Discharge
7 - 10 days
postop.
Follow-up
3
months
Follow-up
12 months
Follow-up
2 years
Follow-up
3 years
Follow-up
4 years
Follow-up
5 years
Clinical examination XX X X
Contact by phone XXX
Metal ion concentrations in plasma XX X
Testing for hypersensitivity X X
Knee Society score XX X X
Oxford score X XXXXXX
UCLA activity score XX X X
SF 36 XX X X
AE/SAE XXXXXXXBMC Musculoskeletal Disorders 2009, 10:128 http://www.biomedcentral.com/1471-2474/10/128
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Current Status and Planning
The study protocol was completed in December 2008.
Preparation of all study-related material was finalised
until February 2009. After approval from the local Ethics
Committee on 26 February 2009, the first patient was
recruited on 27 April 2009 and more patients are currently
being enrolled at the centre. Assuming an enrolment of 6
to 8 patients per month, recruitment is expected to be
completed at the end of 2010.
Discussion
An "ideal" knee prosthesis would prevent release of any
metal ions into the patient's blood and thus protect him/
her from any local or systemic toxic effects, cancer risk or
activation of the immune system possibly resulting in
hypersensitivity against components of the prosthesis.
Although risks of such adverse effects have not been yet
conclusively proven, they cannot be excluded. Therefore,
reduction of metal ion release through coating of an
implant may be an advantage if disadvantages in terms of
premature loosening can be avoided. This underscores the
need to test these new implants in clinical trials.
Conclusion
The present trial is a single-centre, prospective ran-
domised trial to evaluate metal ion release of a novel zir-
conium-coated total knee prosthesis compared to an
uncoated implant of the same geometry. It aims to find
out whether this coated implant can reduce metal ion
release and how both implants compare with respect to
adverse events, functional results and quality of live.
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